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ABSTRACT
Background. Kidney dysfunction is a strong predictor of
end-stage renal disease and cardiovascular (CV) events. The
main goal was to study the clinical correlates of diabetic
kidney disease in a large cohort of patients with type 2 diabetes
mellitus (T2DM) attending 236 Diabetes Clinics in Italy.
Methods. Clinical data of 120 903 patients were extracted from
electronic medical records by means of an ad hoc-developed
software. Estimated glomerular ﬁltration rate (GFR) and in-
creased urinary albumin excretion were considered. Factors
associated with the presence of albuminuria only, GFR < 60
mL/min/1.73 m2 only or both conditions were evaluated
through multivariate analysis.
Results. Mean age of the patients was 66.6 ± 11.0 years, 58.1%
were male and mean duration of diabetes was 11.1 ± 9.4 years.
The frequency of albuminuria, low GFR and both albuminuria
and low GFR was 36.0, 23.5 and 12.2%, respectively. Glycaemic
control was related to albuminuria more than to low GFR, while
systolic and pulse pressure showed a trend towards higher
values in patients with normal kidney function compared with
those with both albuminuria and low GFR. Multivariate logistic
analysis showed that age and duration of disease inﬂuenced
both features of kidney dysfunction. Male gender was associated
with an increased risk of albuminuria. Higher systolic blood
pressure levels were associated with albuminuria, with a 4%
increased risk of simultaneously having albuminuria and low
GFR for each 5 mmHg increase.
Conclusions. In this large cohort of patients with T2DM,
reduced GFR and increased albuminuria showed, at least in part,
different clinical correlates. A worse CV risk proﬁle is associated
with albuminuria more than with isolated low GFR.
Keywords: albuminuria, epidemiology, type 2 diabetes
INTRODUCTION
Chronic kidney disease (CKD) is a major cause of morbidity
and mortality, and its prevalence is rising worldwide, mostly
due to population ageing [1]. Diabetes, a major health
problem with global estimates exceeding 382 million people
[2], also plays a role in increasing the prevalence of CKD. In
fact, ∼40% of patients with diabetes develop diabetic kidney
disease (DKD) resulting in albuminuria, reduction of the
glomerular ﬁltration rate (GFR), or both [3].
DKD represents a relevant burden on the National Health
Services since it is responsible for a large number of all inci-
dent cases of end-stage renal disease (ESRD) (nearly half in
the USA) [4]. In addition, a growing body of evidence indi-
cates that kidney dysfunction contributes signiﬁcantly to the
increase in cardiovascular (CV) risk observed among diabetics.
Several studies have indeed shown that increased urinary
albumin excretion (UAE) [5–8] and reduced GFR [9–11] are
both associated with CV risk factors and are distinct predictors
of cardiovascular events among patients with diabetes. Finally,
DKD implies high costs for the health system [4].
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A recent cross-sectional analysis attempted to deﬁne the
temporal trend in DKD among the general population in the
USA and showed that its prevalence increased from 2.0%
(1988) to 2.8% (2008), which was proportional to the increase
observed in diabetes [12]. Prospective data from the UK Pro-
spective Diabetes Study (UKPDS) showed that over a median
of 15 years of follow-up, 1544 (38%) of 4031 patients with type
2 diabetes and normoalbuminuria at baseline developed albu-
minuria and 1449 (29%) of 5032 with normal serum creatinine
at baseline developed renal impairment [13]. Recent data from
an Italian study (RIACE) which enrolled 15 773 patients with
type 2 diabetes showed that at baseline, 26.9% of patients had
albuminuria and 18.7% had low GFR [14]. Data from this [14]
and other studies [15–17] support the emerging hypothesis
that albuminuria or the isolated reduction of GFR may rep-
resent speciﬁc phenotypes of kidney dysfunction, with differ-
ent correlates and, probably, different outcomes in terms of
renal and cardiovascular risk. Thus, albuminuria and GFR
have been demonstrated to have a different impact on the cor-
onary and peripheral vascular bed, with reduced GFR which
was preferentially associated with a high risk of developing
coronary events [18].
Given the huge burden of DKD, unravelling its principal
epidemiological aspects might help us to better understand the
pathophysiological mechanisms and guide the implemen-
tation of preventive and therapeutic strategies in order to
improve the health outcomes of people with diabetes.
Therefore, the aim of our study is to describe the aggrega-
tion of cardiovascular risk factors among patients with various
features of kidney dysfunction (i.e. albuminuria, reduction of
GFR, or both) in a large cohort of patients with type 2 diabetes
attending out-patient diabetes centres.
MATERIALS AND METHODS
The Italian health-care system
All Italian citizens, regardless of social class or income, are
cared for by a general practitioner as part of the National
Health System. It is estimated that over 3 million citizens
know they are affected by diabetes in Italy. Care for people
with diabetes is mainly provided by a public network of ∼700
diabetes clinics which provide diagnostic conﬁrmation,
therapy, prevention and early diagnosis of complications
through close patient follow-up by a team of specialists. Most
patients are referred to these care units by their general prac-
titioner, and care is free of charge [19, 20].
Patients
In the present report, we describe the results of an analysis
that was carried out using the data set of the electronic
medical records that were collected between 1 January 2009
and 31 December 2009, on a large sample of patients with a di-
agnosis of type 2 diabetes [according to American Diabetes
Association (ADA) 2003 criteria], who attended 236 Diabetes
Clinics in Italy. Approximately, one-third of all the Italian
Diabetes Clinics were involved in the present study. They are
evenly distributed throughout the country. We identiﬁed a
population of 415 346 patients of whom 120 903 aged 18 years
or older with at least 1 outpatient measurement of serum crea-
tinine and albuminuria in the index year (i.e. 2009) were
included in the present analysis. A ﬂow chart of the selection
of the patients is provided in Supplementary data, Appendix.
Albuminuria was based on one measurement, given ﬁndings
supporting the good reproducibility of UAE in spite of the
intra-individual variability and showing that also a single UAE
value represents an accurate predictor of nephropathy stage for
clinical and epidemiological purposes [21].
Methods and data collection
The database utilized derives from the Italian Association
of Clinical Diabetologists [Associazione Medici Diabetologi
(AMD)] initiative which started in 2006 to monitor diabetes
care and quality of care [19, 20]. The aim was to identify a set
of indicators to be used in the context of continuous quality
improvement. All participating clinics used an electronic clini-
cal record system for the everyday management of outpatients,
and a software was speciﬁcally developed to extract infor-
mation from all these clinical databases (AMD data). Data
from all participating clinics were collected anonymously and
were centrally analysed [19, 20].
The core data set included measures and monitoring of gly-
cated haemoglobin (HbA1c), blood pressure, total-cholesterol,
low-density lipoprotein (LDL) cholesterol or high-density
lipoprotein (HDL) cholesterol and triglycerides. The use of
speciﬁc classes of drugs (glucose lowering, lipid lowering and
antihypertensive agents), based on ATC codes, was also evalu-
ated. Current smokers were identiﬁed in the electronic clinical
record based on a speciﬁc Yes/No ﬁeld. In the case of multiple
evaluations during the year, the most recent ones were taken
into consideration for the analysis. Since normal ranges for
glycated haemoglobin, which could not be DCCT aligned in
some centres, varied among the clinics, the percentage change
with respect to the upper normal values was estimated and
multiplied by 6.0 in order to carry out comparison among
clinics [22].
Kidney function was assessed by serum creatinine and UAE
measurements. GFR was estimated for each patient by using
the Chronic Kidney Disease Epidemiology Collaboration
formula derived by serum creatinine values [23]. Increased
UAE (albuminuria) was diagnosed if the urinary albumin con-
centration was >30 mg/L, or if the UAE rate was >20 μg/min,
or if the urinary albumin-to-creatinine ratio (ACR) was >2.5
mg/mmol in men and 3.5 mg/mmol in women.
DKD was deﬁned as diabetes with albuminuria or low GFR
(<60 mL/min/1.73 m2), or both. Information on the presence
of diabetic retinopathy was based on the following ICD-9 CM
codes: 95.03, 95.11, 95.12, 362.01, 362.02, 14.24, 362.83, 369.x
was also available [19, 20]
Statistical analysis
Clinical characteristics are expressed as mean and standard
deviation for continuous variables, and frequencies and per-
centages for categorical ones. Between-group statistical tests
were not applied: in fact, due to the large sample size, even
trivial differences would have reached statistical signiﬁcance.
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Multivariate logistic regression analyses, with backward
variable selection, were performed to evaluate factors indepen-
dently associated with an increased likelihood of having iso-
lated low GFR, isolated albuminuria or the simultaneous
presence of low GFR and albuminuria. The reference category
included patients with absent albuminuria and with GFR≥ 60
mL/min/1.73 m2. The following covariates were tested because
of a proven or suspected relationship with the following out-
comes: age, gender, BMI, diabetes duration, HbA1c, systolic
and diastolic blood pressure, total cholesterol, LDL cholesterol,
HDL cholesterol, triglycerides, retinopathy and glucose-
lowering, lipid-lowering and antihypertensive agents. Results
are expressed as odds ratio and their 95% conﬁdence interval.
RESULTS
The overall frequency of albuminuria, low GFR or both albumi-
nuria and low GFR in our data set was 36.0, 23.5 and 12.2%,
respectively. The main clinical characteristics of the study popu-
lation as a whole and when analysed on the basis of the pres-
ence/absence of albuminuria or low GFR are shown in Table 1.
Overall, the mean age of patients was 66.6 ± 11.0 years, 58.1%
were male, mean duration of diabetes was 11.1 ± 9.4 years,
mean HbA1c 7.5 ± 1.5% and 17.6% were smokers.
Data reported in Table 1 show some relevant differences
among subgroups of patients. In fact, patients with reduced
GFR were more likely to be women and, on the average, older
when compared with those with albuminuria. The simul-
taneous presence of albuminuria and low GFR was in general
higher in the elderly, but the occurrence of isolated albumi-
nuria and reduction of GFR changed on the basis of age, being
32 and 8.3% in patients <65 years of age and 39 and 33% in
those >65, respectively (data not shown). It is noteworthy that
13 660 patients (11%) had an isolated reduction of GFR, i.e.
low GFR and normoalbuminuria. This represents about half
(48%) of the whole population with low GFR and 18% of
those with normoalbuminuria. When compared with patients
with both low GFR and albuminuria, diabetic patients with
isolated reduction of GFR were more often females, showed
similar age, shorter duration of diabetes, higher GFR, lower
HbA1c, lower systolic blood pressure (SBP), lower triglycerides
and higher HDL cholesterol (Table 1).
While worse glycaemic control shows a stronger association
with albuminuria, regardless of the presence of low GFR, both
systolic and pulse pressure showed a trend towards higher
values in patients with one feature of kidney dysfunction, with
the highest values being observed in those with both com-
ponents of DKD. This occurred despite a parallel trend towards
greater prevalence and intensity (i.e. number of drugs, data not
shown) of antihypertensive treatment (Table 2). A more athero-
genic lipid proﬁle, i.e. higher triglycerides and lower HDL
cholesterol, was clearly associated with kidney dysfunction,
while total, as well as LDL cholesterol levels were similar in
patients with and without DKD, although a greater prevalence
of treatment with statins was recorded in the subgroup with
either one or both renal abnormalities (Tables 1 and 2).
As expected, patients with both albuminuria and low GFR
received more intensive glucose-lowering, lipid-lowering and
antihypertensive treatment (Table 2); comparing the two
groups with one kidney impairment, only small differences
were found in terms of lipid-lowering and antihypertensive
treatment, while insulin therapy was more frequent in patients
with low GFR. As expected, therapy with ACE inhibitors or
angiotensin receptor blockers was more frequent in individ-
uals with albuminuria.
The relationship between traits of DKD and traditional dia-
betes and cardiovascular risk factors was further investigated by
multivariate logistic analysis. Age and duration of disease inde-
pendently affected both features of kidney dysfunction (Table 3).
Being female represented a risk factor for isolated low GFR
(males versus females: OR = 0.69, 95% CI 0.64–0.73), while male
Table 1. Clinical features of 120 903 patients with type 2 diabetes: whole sample and divided according to the presence/absence of albuminuria or low eGFR
Whole sample Alb− and low eGFR− Alb− and low eGFR+ Alb+ and low eGFR− Alb+ and low eGFR+
n (%) 120 903 63 639 (52.6%) 13 660 (11.3%) 28 806 (23.8%) 14 684 (12.2%)
Male gender n (%) 70 247 (58.1) 35 822 (56.3) 5 776 (42.2) 19 874 (69.0) 8741 (59.5)
Age (years) 66.6 ± 11.0 64.1 ± 10.7 74.0 ± 8.0 65.0 ± 10.8 73.4 ± 8.5
BMI (kg/m2) 29.7 ± 5.2 29.4 ± 5.2 29.7 ± 5.1 30.2 ± 5.3 30.0 ± 5.2
Serum creatinine (mg/dL) 1.0 ± 0.5 0.8 ± 0.2 1.3 ± 0.5 0.9 ± 0.2 1.6 ± 0.8
eGFR 75.5 ± 1.5 85.1 ± 13.9 48.0 ± 9.8 84.1 ± 14.4 42.8 ± 12.7
Known duration of diabetes (years) 11.1 ± 9.4 9.7 ± 8.6 13.3 ± 10.4 11.0 ± 9.0 15.3 ± 10.5
HbA1c (%) 7.5 ± 1.5 7.4 ± 1.5 7.4 ± 1.4 7.8 ± 1.6 7.7 ± 1.5
Total cholesterol (mg/dL) 186.6 ± 41.0 187.9 ± 40.0 185.7 ± 40.7 185.6 ± 42.3 183.4 ± 42.7
Triglycerides (mg/dL) 148.1 ± 108.2 139.4 ± 99.7 151.1 ± 87.4 157.2 ± 131.0 166.6 ± 108.1
HDL cholesterol (mg/dL) 49.2 ± 13.6 50.4 ± 13.7 49.6 ± 13.8 47.7 ± 13.2 46.5 ± 13.4
LDL cholesterol (mg/dL) 108.2 ± 34.2 110.0 ± 33.8 106.4 ± 34.1 107.1 ± 34.9 103.9 ± 34.4
SBP (mmHg) 139.6 ± 19.1 137.7 ± 18.3 139.5 ± 18.9 141.5 ± 19.5 143. 8 ± 20.5
DBP (mmHg) 79.2 ± 9.8 79.1 ± 9.5 77.3 ± 9.8 80.5 ± 10.0 78.5 ± 10.3
Pulse pressure (mmHg) 60.5 ± 16.5 58.7 ± 15.7 62.3 ± 16.6 61.1 ± 16.6 65.4 ± 18.0
Retinopathy 18.6 14.2 18.5 22.4 30.5
Smokers (%) 17.6 17.5 8.8 23.8 13.4
Alb−, normoalbuminuria; Alb+, albuminuria; eGFR, estimated glomerular ﬁltration rate; BMI, body mass index; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein
cholesterol; LDL, low-density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure All the between-group differences are statistically signiﬁcant with
P < 0.0001.
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gender was associated with an increased risk of albuminuria
(males versus females: OR = 1.89, 95% CI 1.81–1.98). Worse gly-
caemic control also affected the presence of albuminuria with an
increased risk of 7% for every 1% increase in HbA1c (OR = 1.07,
95% CI 1.05–1.09), while it was inversely associated with the risk
of low GFR (OR = 0.96, 95% CI 0.93–0.98).
Higher SBP levels were associated with albuminuria, with a
4% greater risk of simultaneously having albuminuria and low
GFR for each increase of 5 mmHg. It is noteworthy that the
use of antihypertensive drugs was related to both features of
kidney dysfunction.
Renal dysfunction was also associated with the typical
atherogenic lipid proﬁle. In fact, HDL-cholesterol levels were
inversely related to the risk of kidney abnormalities, while high
levels of triglycerides were directly associated with an in-
creased probability of having albuminuria. The risk of albumi-
nuria and low GFR increased by 3% for every 10 mg/dL
increase in triglycerides. Smoking was clearly associated with
albuminuria and increased the risk by 55%, while the use of
drugs inhibiting the renin–angiotensin system (i.e. ACE
inhibitors or angiotensin receptor blockers) was associated
with both low GFR and albuminuria.
Table 2. Percentage of patients with T2DM treated with glucose lowering, lipid lowering and antihypertensive agents in the whole sample and in the
subgroups of patients divided according to the presence/absence of Albuminuria and low eGFR
Whole sample Alb− and low eGFR- Alb− and low eGFR+ Alb+ and low eGFR− Alb+ and low eGFR+
Glucose-lowering Rx
Diet (%) 6.3 7.9 6.3 4.2 3.7
OHA (%) 60.2 66.8 54.0 59.7 38.7
OHA + insulin (%) 17.0 14.4 16.0 22.2 19.2
Insulin (%) 16.5 10.9 23.7 13.9 38.4
Dyslipidaemia
Lipid-lowering treatment (%) 49.3 46.2 51.0 52.1 55.7
Treatment with statins (%) 45.0 42.5 45.8 47.6 49.8
Treatment with ﬁbrates 2.7 2.4 3.5 2.7 3.2
Arterial hypertension
Antihypertensive treatment 67.0 58.4 76.9 72.8 84.0
Treatment with ACE-Is/ARBs 61.1 50.9 68.5 70.3 80.3
Antiplatelet Rx
Aspirin 33.5 30.7 36.0 35.6 39.1
Alb−, normoalbuminuria; Alb+, albuminuria; eGFR, estimated glomerular ﬁltration rate; OHA, oral hypoglycaemic agents; ACE-Is, angiotensina converting enzyme-inhibitors; ARBs,
angiotensina II receptor antagonists.
Table 3. Results of multivariate logistic regression analysis (backward models) showing the relationship between traits of DKD and traditional diabetic and
cardiovascular risk factors. Reference category for all were patients with normoalbuminuria and eGFR≥ 60 mL/min/1.73 m2.
Dependent variables
Low eGFR normal
albuminuria
Albuminuria normal eGFR Low eGFR and albuminuria
Independent variables OR 95%CI OR 95% CI OR 95% CI
Age (by 1 year) 1.12 1.11–1.12 1.01 1.01–1.01 1.12 1.12–1.13
DBP (by 5 mmHg) 0.97 0.95–0.99 1.04 1.03–1.05 NS NS
SBP (by 5 mmHg) 0.98 0.97–0.99 1.03 1.02–1.03 1.04 1.04–1.05
Total cholesterol (by 10 mg/dL) 1.04 1.02–1.07 1.05 1.04–1.06 1.07 1.04–1.10
HDL-C (by 5 mg/dL) 0.93 0.92–0.95 0.95 0.94–0.96 0.88 0.86–0.89
LDL-C (by 10 mg/dL) 0.96 0.93–0.98 0.95 0.94–0.96 0.94 0.91–0.96
Triglycerides (by 10 mg/dL) 1.02 1.02–1.03 NS NS 1.03 1.02–1.03
BMI (by 1 kg/m2) 1.03 1.02–1.03 1.03 1.02–1.03 1.05 1.04–1.05
Duration of diabetes (by 1 year) 1.01 1.00–1.01 1.01 1.01–1.01 1.02 1.01–1.02
HbA1c (by 1%) 0.96 0.93–0.98 1.07 1.05–1.09 0.97 0.95–1.00
Males versus females 0.69 0.64–0.73 1.89 1.81–1.98 1.52 1.42–1.63
Smokers (yes versus no) 0.84 0.76–0.93 1.55 1.47–1.64 1.22 1.11–1.34
Oral agents versus diet 0.88 0.78–0.99 1.47 1.34–1.62 1.14 0.98–1.32
Oral agents + insulin versus diet 1.09 0.93–1.26 2.12 1.90–2.37 2.01 1.70–2.39
Insulin versus diet 2.06 1.78–2.38 1.96 1.75–2.20 5.59 4.74–6.59
Use of antihypertensive drugs 1.60 1.42–1.80 1.36 1.26–1.48 2.67 2.34–3.05
Use of ACE inhibitors and/or ARBs 1.24 1.13–1.37 1.33 1.23–1.42 1.24 1.12–1.36
Use of statins 1.10 1.03–1.17 NS NS 1.17 1.09–1.25
Retinopathy NS NS 1.41 1.33–1.49 1.64 1.52–1.77
OR, odds ratio; 95% CI, 95% conﬁdence of intervals; DKD, diabetic kidney disease; eGFR, estimated glomerular ﬁltration rate; BMI, body mass index; HbA1c, glycated
haemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure; ACE,
angiotensin converting enzyme; ARBs, angiotensin receptor blockers.
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Finally, as expected, the use of insulin was strongly associ-
ated with more advanced renal dysfunction.
CONCLUSIONS
We analysed data derived from a large database providing
important hints regarding factors associated with different
types of DKD.
Overall, patients with DKD showed an unfavourable CV
risk proﬁle with regard to glucose control, lipid proﬁle and
blood pressure despite similar treatment when compared with
those without renal involvement, although with some
peculiarities. Interestingly, the occurrence of isolated albumi-
nuria seems to be associated with a much worse risk proﬁle
(i.e. higher values of HbA1c, worse triglycerides and HDL
cholesterol and blood pressure levels) when compared with
the presence of isolated GFR reduction. While the cross-
sectional design of the study does not allow to draw any patho-
genetic conclusions, our ﬁndings are in agreement with the
unfavourable prognostic power of macroalbuminuria that was
observed in recent meta-analyses [24].
Furthermore, although albuminuria and reduced GFR are
independently related to an increased cardiovascular risk
proﬁle, they also show different clinical correlates, suggesting
that these two well-known prognostic markers may—at least
in part—recognize different pathogenetic mechanisms. Again,
this is in keeping with the results of the CKD Consortium
meta-analysis [24] indicating that these two markers of renal
damage actually do carry independent prognostic information.
The presence of DKD entails a signiﬁcantly worse outcome
in patients with diabetes, and although microalbuminuria has
been shown to progress to overt proteinuria and progressive
renal failure only in a limited number of patients, it is widely
known to be the harbinger of greater CV morbidity and mor-
tality. Thus, our data showing a relatively high prevalence of
renal abnormalities in diabetic patients attending out-patient
clinics in Italy support the need to implement more effective,
large-scale, preventive and therapeutic strategies. Greater em-
phasis should especially be placed on preventing the onset of
increased urine albumin excretion since this condition seems
to be a feature of a more unfavourable CV risk phenotype, and
is associated with worse metabolic control and higher BP
values despite more vigorous treatment.
Recent studies have highlighted the large number of dia-
betic individuals with low GFR in the absence of elevated UAE
(the so-called non-albuminuric renal impairment) [14–17].
Again, our ﬁndings are in agreement with those reported by
the UKPDS which showed that half of the patients with low
GFR are normoalbuminuric [13]. The role of this renal con-
dition in terms of clinical outcome is still not completely clear.
However, our results which show better glycaemic and blood
pressure control as well as better lipid proﬁle among patients
with non-albuminuric renal impairment suggest a minor CV
risk in the absence of albuminuria, in agreement with Rigal-
leau et al. [16], who showed, in a relatively small cohort of
patients, that the risk of DKD progression or death is lower in
patients with normoalbuminuria when compared with those
with both low GFR and albuminuria.
Our ﬁnding of relatively lower blood pressure levels in the
subset of patients with isolated GFR abnormalities might also
suggest different pathogenetic mechanisms and features at the
renal level, possibly characterized by haemodynamic changes
(hypoperfusion) rather than atherosclerotic ones in the absence
of albuminuria.
As expected, smoking is associated with albuminuria alone
or in combination with low GFR while, not surprisingly, we found
a lower prevalence of patients with isolated low GFR among
smokers. This ﬁnding supports the hypothesis of Chuahirun et al.
[25] who found in patients with type 2 diabetes that the effect of
smoking was mediated by albuminuria. Using drugs inhibiting the
renin–angiotensin system was associated with an excess risk of
having impaired renal function; this is likely due to indication bias.
It is worth to note that the overall percentage of patients
under lipid lowering or ACE/ARB anti-hypertensive medications
was relatively low in our cohort, despite the recommendations of
guidelines, speciﬁcally in the presence of diabetes and microalbu-
minuria. As a matter of fact, a number of studies have identiﬁed
gaps in prescribers’ adherence to clinical guideline recommen-
dations, also among patients with diabetic nephropathy [26–32].
Our study has several limitations as well as strengths that
deserve to be acknowledged and commented upon. First of all,
laboratory parameters were not measured in a single centralized
laboratory and this may have led to considerable variability,
especially in the evaluation of serum creatinine (and therefore
GFR estimation). Although creatinine determination cannot
always be referred to IDMS procedures, most laboratories around
the country currently use the Jaffè method which has been shown
to have good reproducibility. In addition, we have information on
albuminuria only as a categorical trait. One more limitation is the
missing data on previous CVH/IHD event.
On the other hand, the large size of the database and the
homogeneous geographical distribution of the recruiting centres
are clearly major strengths of the study.
In conclusion, in this large cohort of patients with T2DM,
reduced GFR and increased albuminuria show, at least in part,
different clinical correlates. In fact, while systolic and diastolic
blood pressure, glucose control and lipids (i.e. total and HDL
cholesterol) are associated with isolated albuminuria, only
lipids (i.e. total and HDL-cholesterol and triglycerides) appear
to affect isolated low GFR. This result underlines the relevant
role of albuminuria whose association with an unfavourable
burden of CV risk factors seems to be even stronger than that
of a reduction in GFR.
Greater therapeutic emphasis should be placed on the
implementation of therapeutic strategies to correct modiﬁable
risk factors and prevent CV diseases in the presence of DKD,
especially in those with albuminuria.
SUPPLEMENTARY DATA
Supplementary data are available online at http://ndt.
oxfordjournals.org.
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